Project Grant R43GM149096
- This Project Grant award, made by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of Dermisphere, an advanced dermal regeneration scaffold product by Fesariustherapeutics Inc. The $349,345 award aims to demonstrate the feasibility of using Dermisphere to manage acute major burn wounds. Preliminary studies have shown that Dermisphere can support rapid and sustained cellular...
- Federal Project Grant Award Summary Treysta Medical Technologies Inc. received a $304,984 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), effective October 1, 2025, through September 30, 2026. The award funds development of a novel burn care therapeutic system designed to prevent fibrotic pathologies and reduce scarring in serious burn injuries. The deliverables...
- Insoma Bio, Inc. received a $252,992 National Science Foundation Engineering Division Project Grant to develop an injectable protein matrix to enhance the stability of autologous fat grafts. The goal of the one-year grant project, which runs from July 2021 through June 2022, is to create a biocompatible hydrogel scaffold for adipose tissue engineering that can improve the survival rate of fat transfer procedures. The NSF Engineering Division seeks to foster innovation in engineering research...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded Collamedix Inc. a $300,000 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to establish the feasibility of their "CollaLink" collagen-based scaffold for augmenting primary repair of anterior cruciate ligament (ACL) mid-substance tears. The project aims to demonstrate that the CollaLink scaffold, when placed around an ACL tear, can provide a...
- Federal Grant Award Summary Perfusio Corp. received a $349,910 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) awarded on September 17, 2025, with a completion date of September 16, 2026. The company is developing a cost-effective, handheld multi-spectral artificial intelligence/machine learning-powered device for burn and wound evaluation. Leveraging Perfusio's Multi-Spectral Physiologic...
- The National Science Foundation (NSF) awarded a $275,000 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Auxilium Health, Inc. for the development and validation of an aerogel-based biomaterial wound dressing. The proposed innovation aims to create a multi-layer wound dressing platform with integrated fluid management, biofilm prevention, and rapid infection detection capabilities to improve the management of acute wounds, chronic wounds, surgical...
- Federal Project Grant Award Summary Matregenix Inc. received a $1.952 million Project Grant from the National Institute of Dental and Craniofacial Research under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded July 1, 2025, with completion scheduled for June 30, 2027. This Phase II grant funds the development and large animal study validation of MATRINOVA, an animal-free, amino acid-based bilayered barrier membrane designed for guided bone regeneration in oral and...
- Federal Grant Award Summary Epoulosis Therapeutics Inc. received a $2.05 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded August 1, 2025, with completion targeted for July 31, 2027. The award funds the development of a novel therapeutic wound bandage for diabetic foot ulceration (DFU) treatment that employs advanced biomaterials capable of...
- Federal Grant Award Summary Fesariustherapeutics Inc. received a $349,892 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2026. The award supports the development of Dermisphere Shield, an antimicrobial dermal regeneration template designed to address complex wound healing challenges in contaminated or potentially contaminated...
- This $100,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program will support the development of an advanced wound care technology at Florida International University. Specifically, the university will create a bandage-integrated platform that provides feedback-mediated wound therapy to enable personalized care. The conformable platform is designed to non-invasively monitor multiple wound biomarkers in spatial detail and then apply targeted...
A RECOMBINANT ELASTIN SKIN SUBSTITUTE FOR THE TREATMENT OF BURNS - PROJECT SUMMARY THE GOAL OF THIS PROJECT IS TO OPTIMIZE AND EVALUATE INSOMA BIO'S PROPRIETARY RECOMBINANT ELASTIN-BASED BIOMATERIAL, FRACTOMER, AS AN EFFECTIVE, LOW-COST SKIN GRAFTING SUPPORT MATRIX FOR THE TREATMENT OF SEVERE BURN WOUNDS. BURNS ARE MOST SUCCESSFULLY TREATED BY SURGICAL EXCISION FOLLOWED BY SKIN GRAFTING; HOWEVER MANY PATIENTS WITH SEVERE DAMAGE DO NOT HAVE SUFFICIENT HEALTHY SKIN TO SUPPORT AUTOGRAFT PROCEDURES. TO ADDRESS THIS NEED, BIOMATERIAL MATRICES, SUCH AS INTEGRA WOUND MATRIX, HAVE BEEN DEVELOPED WHICH REDUCE INFECTION, FACILITATE VASCULARIZATION, AND SUPPORT REGENERATION OF DERMIS TISSUE WHEN APPLIED TO BURN WOUNDS. THE CURRENT MARKET FOR DERMAL REPLACEMENT, VALUED AT OVER $7 BILLION, IS DOMINATED BY ANIMAL-DERIVED COLLAGEN DUE TO WELL ESTABLISHED PROCESSES FOR ISOLATING COLLAGEN FROM TISSUE AND HISTORICAL PRECEDENT FOR SAFETY. HOWEVER, DUE TO THE COST OF HARVEST FROM ANIMALS, THEY ARE NOTORIOUSLY EXPENSIVE, WITH A SINGLE 40 CM2 SHEET OF INTEGRA COSTING THE PATIENT ~$10K. IN ADDITION, COLLAGEN CANNOT REPLICATE THE ELASTICITY OF NATURAL SKIN, WITH ELASTIN, NOT COLLAGEN, PROVIDING SKIN WITH ITS RESILIENT AND PLIABLE PROPERTIES. AS ELASTIN PRODUCTION ALL BUT HALTS IN ADULTHOOD, CONTRACTION DUE TO LACK OF ELASTIN LEADS TO SCARING IN NEWLY DEVELOPED SKIN. AS A RESULT, AT LEAST ONE THIRD OF BURN TREATMENTS USING THESE MATERIALS REQUIRE SURGICAL REVISION. INSOMA'S FRACTOMER BIOMATERIAL IS MADE FROM RECOMBINANT ELASTIN-MIMETIC PROTEINS AND REPRESENTS AN IDEAL SUBSTRATE FOR THE PRODUCTION OF NEW SKIN GRAFTING MATRICES WHICH BETTER REPLICATE THE UNIQUE BIOMECHANICAL PROPERTIES OF SKIN. THE MATERIAL HAS BEEN SHOWN TO SUPPORT IN VIVO CELLULAR INFILTRATION, ORGANIZED COLLAGEN DEPOSITION, VASCULARIZATION, AND BIOCOMPATIBILITY DURING IN VIVO TESTING IN BOTH MURINE AND PORCINE MODELS AND, DUE TO ITS TEMPERATURE-SENSITIVE PHASE TRANSITION PROPERTIES, CAN BE READILY MOLDED INTO VIRTUALLY ANY FORM INCLUDING SKIN-LIKE SHEETS. DURING THE PHASE I PROGRAM PROPOSED HERE, THE COMPANY WILL CONTINUE OPTIMIZING FRACTOMER SHEET STRUCTURE AND FORMATION METHODS TO PRODUCE A MATERIAL WHICH SUPPORTS DERMAL REGENERATION THROUGH VASCULARIZATION, CELLULAR INFILTRATION, AND ORGANIZED COLLAGEN DEPOSITION. A PORCINE MODEL OF BURN WOUNDS WILL BE USED TO COMPARE FRACTOMER TO INTEGRA WOUND MATRIX, THE CURRENT GOLD STANDARD IN SKIN GRAFTING SUPPORT MATRICES. THE EXPECTED IMPROVEMENT IN GRAFT OUTCOMES (E.G., FEWER CONTRACTIONS AND NO OUTRIGHT REJECTIONS) BY EMPLOYING THE ELASTIN-BASED FRACTOMER GRAFT MATERIAL REPRESENTS A HIGHLY DISRUPTIVE PRODUCT TO THE CURRENT DERMAL REPAIR MATRIX MARKET.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 7/2/25 | ||
| Not listed | $0 | 4/1/24 | ||
| Not listed | $282.4k | 3/31/23 | ||
| Not listed | $282.4k | 3/31/23 |